These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 25350366)
41. Energy metabolism, leptin, and biochemical parameters are altered in rats subjected to the chronic administration of olanzapine. Zugno AI; Barcelos M; Oliveira Ld; Canever L; Luca RD; Fraga DB; Matos MP; Rezin GT; Scaini G; Búrigo M; Streck EL; Quevedo J Braz J Psychiatry; 2012 Jun; 34(2):168-75. PubMed ID: 22729413 [TBL] [Abstract][Full Text] [Related]
42. A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels. Roerig JL; Steffen KJ; Mitchell JE; Crosby RD; Gosnell BA J Clin Psychopharmacol; 2008 Feb; 28(1):21-6. PubMed ID: 18204336 [TBL] [Abstract][Full Text] [Related]
43. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798 [TBL] [Abstract][Full Text] [Related]
44. Inhibition of olanzapine-induced weight gain by the retinoid analog AM-80. Richards M; Chiba S; Ninomiya M; Wakabayasi C; Kunugi H Pharmacopsychiatry; 2013 Nov; 46(7):267-73. PubMed ID: 24105080 [TBL] [Abstract][Full Text] [Related]
45. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Saddichha S; Ameen S; Akhtar S J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337 [TBL] [Abstract][Full Text] [Related]
46. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. Hosojima H; Togo T; Odawara T; Hasegawa K; Miura S; Kato Y; Kanai A; Kase A; Uchikado H; Hirayasu Y J Psychopharmacol; 2006 Jan; 20(1):75-9. PubMed ID: 16204328 [TBL] [Abstract][Full Text] [Related]
47. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Han M; Deng C; Burne TH; Newell KA; Huang XF Psychoneuroendocrinology; 2008 Jun; 33(5):569-80. PubMed ID: 18358632 [TBL] [Abstract][Full Text] [Related]
48. Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. Fell MJ; Marshall KM; Williams J; Neill JC J Psychopharmacol; 2004 Jun; 18(2):149-55. PubMed ID: 15260902 [TBL] [Abstract][Full Text] [Related]
49. Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics. Cuerda C; Merchan-Naranjo J; Velasco C; Gutierrez A; Leiva M; de Castro MJ; Parellada M; Giráldez M; Bretón I; Camblor M; García-Peris P; Dulín E; Sanz I; Desco M; Arango C Clin Nutr; 2011 Oct; 30(5):616-23. PubMed ID: 21492975 [TBL] [Abstract][Full Text] [Related]
50. Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study. Hunt HJ; Donaldson K; Strem M; Tudor IC; Sweet-Smith S; Sidhu S J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):632-637. PubMed ID: 34369902 [TBL] [Abstract][Full Text] [Related]
51. A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. Roerig JL; Mitchell JE; de Zwaan M; Crosby RD; Gosnell BA; Steffen KJ; Wonderlich SA J Clin Psychopharmacol; 2005 Oct; 25(5):413-8. PubMed ID: 16160615 [TBL] [Abstract][Full Text] [Related]
52. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033 [TBL] [Abstract][Full Text] [Related]
53. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317 [TBL] [Abstract][Full Text] [Related]
54. Amantadine for weight gain associated with olanzapine treatment. Deberdt W; Winokur A; Cavazzoni PA; Trzaskoma QN; Carlson CD; Bymaster FP; Wiener K; Floris M; Breier A Eur Neuropsychopharmacol; 2005 Jan; 15(1):13-21. PubMed ID: 15572269 [TBL] [Abstract][Full Text] [Related]
56. The role of conjugated linoleic acid in reducing body fat and preventing holiday weight gain. Watras AC; Buchholz AC; Close RN; Zhang Z; Schoeller DA Int J Obes (Lond); 2007 Mar; 31(3):481-7. PubMed ID: 16924272 [TBL] [Abstract][Full Text] [Related]
57. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Mauri M; Simoncini M; Castrogiovanni S; Iovieno N; Cecconi D; Dell'Agnello G; Quadrigli M; Rossi A; Donda P; Fagiolini A; Cassano GB Pharmacopsychiatry; 2008 Jan; 41(1):17-23. PubMed ID: 18203047 [TBL] [Abstract][Full Text] [Related]
58. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413 [TBL] [Abstract][Full Text] [Related]
59. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. Deng C; Lian J; Pai N; Huang XF J Psychopharmacol; 2012 Sep; 26(9):1271-9. PubMed ID: 22695490 [TBL] [Abstract][Full Text] [Related]
60. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Teff KL; Rickels MR; Grudziak J; Fuller C; Nguyen HL; Rickels K Diabetes; 2013 Sep; 62(9):3232-40. PubMed ID: 23835329 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]